お知らせ • May 11
CareRx Corporation announces Quarterly dividend, payable on July 09, 2026 CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on July 09, 2026, ex-date on June 23, 2026 and record date on June 23, 2026. お知らせ • Apr 28
CareRx Corporation to Report Q1, 2026 Results on May 06, 2026 CareRx Corporation announced that they will report Q1, 2026 results After-Market on May 06, 2026 お知らせ • Mar 17
CareRx Corporation, Annual General Meeting, May 28, 2026 CareRx Corporation, Annual General Meeting, May 28, 2026. お知らせ • Mar 10
CareRx Corporation announces Quarterly dividend, payable on April 09, 2026 CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on April 09, 2026, ex-date on March 19, 2026 and record date on March 19, 2026. お知らせ • Feb 25
CareRx Corporation to Report Q4, 2025 Results on Mar 04, 2026 CareRx Corporation announced that they will report Q4, 2025 results After-Market on Mar 04, 2026 お知らせ • Dec 17
CareRx Corporation announces Quarterly dividend, payable on January 21, 2026 CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on January 21, 2026, ex-date on December 23, 2025 and record date on December 23, 2025. お知らせ • Oct 24
CareRx Corporation to Report Q3, 2025 Results on Nov 03, 2025 CareRx Corporation announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 03, 2025 お知らせ • Sep 17
CareRx Corporation announces Quarterly dividend, payable on October 15, 2025 CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on October 15, 2025, ex-date on September 23, 2025 and record date on September 23, 2025. お知らせ • Jul 21
CareRx Corporation to Report Q2, 2025 Results on Jul 30, 2025 CareRx Corporation announced that they will report Q2, 2025 results After-Market on Jul 30, 2025 お知らせ • May 01
CareRx Corporation to Report Q1, 2025 Results on May 07, 2025 CareRx Corporation announced that they will report Q1, 2025 results at 7:00 AM, US Eastern Standard Time on May 07, 2025 お知らせ • Mar 25
CareRx Corporation, Annual General Meeting, Jun 05, 2025 CareRx Corporation, Annual General Meeting, Jun 05, 2025. お知らせ • Feb 26
CareRx Corporation to Report Q4, 2024 Results on Mar 05, 2025 CareRx Corporation announced that they will report Q4, 2024 results at 7:00 AM, US Eastern Standard Time on Mar 05, 2025 お知らせ • Oct 31
CareRx Corporation to Report Q3, 2024 Results on Nov 08, 2024 CareRx Corporation announced that they will report Q3, 2024 results at 7:00 AM, Eastern Standard Time on Nov 08, 2024 お知らせ • Sep 05
CareRx Corporation Appoints Suzanne Brand as Chief Financial Officer, Effective October 1, 2024 CareRx Corporation announced that following an extensive executive search process, Suzanne Brand will be joining the Company in the role of Chief Financial Officer effective October 1, 2024. Ms. Brand is a highly accomplished executive, bringing a wealth of financial, healthcare and leadership experience. She joins CareRx from Teva Pharmaceuticals, a leading global manufacturer of quality generic and innovative pharmaceuticals, where she has held several senior finance roles since 2011, most recently serving as CFO of Teva Canada. Prior to joining Teva, Ms. Brand spent twelve years in finance at Wyeth Pharmaceuticals, a Pfizer company, where she held senior roles including as a Director, Commercial and Corporate Finance. She began her career as an auditor at PriceWaterhouseCoopers (PwC). Ms. Brand is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA) and holds a Bachelor of Science degree in Biology and Business from the University of Toronto. お知らせ • Aug 02
CareRx Corporation to Report Q2, 2024 Results on Aug 08, 2024 CareRx Corporation announced that they will report Q2, 2024 results at 7:00 AM, US Eastern Standard Time on Aug 08, 2024 お知らせ • May 30
CareRx Corporation Announces Board Changes CareRx Corporation announced that as part of the Company's commitment to Board refreshment and to realign Board functions to match the Company's strategic focus on operational performance, Kevin Dalton, Chairman of the Board for the last six years, will be retiring as Chairman effectively immediately. Mr. Dalton will be succeeded by Jeff Watson, a current independent director of the Board. Mr. Dalton will be stepping into the role as Chair of the Compensation, Nominating and Governance Committee in place of Maria Perrella, who will continue to remain Chair of the Audit Committee. Mr. Watson has served on the Board of CareRx since 2023 and brings over three decades of experience in the healthcare industry, having most recently served as the President and CEO of Apotex from 2018 to 2023. Mr. Watson currently represents SK Capital Partners on two of their portfolio company boards for Apotex and Woodstock Sterile Solutions, and has previously served on numerous other boards, including as a board member and Chair of the Association for Accessible Medicines (AAM), Chair of the Canadian Generic Pharmaceutical Association (CGPA), and former Chair of the US Healthcare Distribution Alliance's (HDA) knowledge partner, the HDA Research Foundation. お知らせ • May 15
CareRx Corporation Announces CFO Transition CareRx Corporation announced that Andrew Mok will step down as Chief Financial Officer effective June 7, 2024, to pursue another employment opportunity. The Company is undertaking a search for a new CFO. Davide Pernarella, currently Vice President, Business Planning and Analysis at CareRx, will assume the role of Interim Chief Financial Officer following Mr. Mok's departure. Mr. Pernarella has worked at CareRx for over seven years in various roles with increasing responsibility, and has an intimate knowledge of the financial and business affairs of the Company. Prior to joining CareRx, he held roles in the Transaction Services and Assurance groups at KPMG Canada. Mr. Pernarella is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA) and holds a Bachelor of Commerce degree from the Rotman School of Management at the University of Toronto. お知らせ • Mar 15
CareRx Corporation, Annual General Meeting, May 28, 2024 CareRx Corporation, Annual General Meeting, May 28, 2024. お知らせ • Mar 08
CareRx Corporation Reports Goodwill and Intangible Assets Impairment Charges for the Fourth Quarter Ended December 31, 2023 CareRx Corporation reported goodwill and intangible assets impairment of $710,000 for the fourth quarter ended December 31, 2023. お知らせ • Mar 01
CareRx Corporation to Report Q4, 2023 Results on Mar 07, 2024 CareRx Corporation announced that they will report Q4, 2023 results at 7:00 AM, US Eastern Standard Time on Mar 07, 2024 お知らせ • Nov 02
CareRx Corporation to Report Q3, 2023 Results on Nov 08, 2023 CareRx Corporation announced that they will report Q3, 2023 results at 7:00 AM, US Eastern Standard Time on Nov 08, 2023 お知らせ • Aug 04
CareRx Corporation to Report Q2, 2023 Results on Aug 10, 2023 CareRx Corporation announced that they will report Q2, 2023 results at 7:00 AM, US Eastern Standard Time on Aug 10, 2023 お知らせ • Jun 07
Carerx Corporation Announces Director Changes CareRx Corporation appointed Puneet Khanna and Jeff Watson as directors. Company announced that Matt Hills did not stand for re-election. お知らせ • Jan 19
CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million. CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 2,963,000
Price\Range: CAD 2.7
Discount Per Security: CAD 0.162 お知らせ • May 21
CareRx Corporation announced that it has received CAD 63.250644 million in funding from Yorkville Asset Management Inc. On May 19, 2021, CareRx Corporation (TSX:CRRX) closed the transaction. The company issued a total of 12,524,880 subscription receipts for gross proceeds of CAD 63,250,644. The transaction included a portion of non-brokered placement from returning investor Yorkville Asset Management Inc. for 2,277,230 subscription receipts for proceeds of CAD 11,500,011.5 and brokered portion of 10,247,650 subscription receipts for proceeds of CAD 51,750,632.5.